Bone Biologics Corp

Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

The stock price of Bone Biologics (BBLG) dropped by 35.53% in the most recent trading session. This is why.

Bone Biologics (BBLG) Stock: Why It Dropped 35.53%

BURLINGTON, Mass.--(BUSINESS WIRE)--Reissuing release to remove "million" after "$5,100,000" in the headline and first sentence of the text. The updated release reads: BONE BIOLOGICS PRICES $5,100,000 UNDERWRITTEN PUBLIC OFFERING Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,1

CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering

JERSEY CITY, N.J. , Oct. 7, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion, announced the pricing of an underwritten public offering of 3,777,778 units at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 before deducting underwriting discounts and commissions and other offering expenses.

WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of: (i) one share of common stock; (ii) one Series A warrant to

Bone Biologics Prices $5,100,000 Million Underwritten Public Offering

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's president and chief executive officer, has been invited to present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30, 2022. A pre-recorded presentation will be available for 72 hours beginning Monday, March 28th at 9:00 a.m. Eastern time. Interested

Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Humanigen

Kiora Pharmaceuticals

Ra Medical Systems Inc

Biotech penny stocks to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Biotech Stocks To Watch Right Now

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with MTF Biologics for demineralized bone matrix (DBM). MTF Biologics is a global nonprofit organization that provides one of the orthopedic industry's largest portfolios of allograft tissue. Bone Biologics is developing a bone graft substitute product consisting of rhNELL-1 and a carrier, to be supplied b

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

Today, investors in Bone Biologics and BBLG stock are seeing some serious gains as investors dive into niche small caps. The post BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today appeared first on InvestorPlace.

BBLG Stock Alert: 7 Things to Know as Bone Biologics Skyrockets Today

Adamis Pharmaceuticals

Ocugen, Inc.

These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch With the Stock Market Down Today

Newly listed Bone Biologics Corporation (NASDAQ: BBLG) shares are surging after the Company announced to present at the H.C. Wainwright BioConnect Virtual Conference.

Why Are Bone Biologics Shares Surging On Monday?

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 – 13, 2022. A pre-recorded presentation will be available beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

The share price of BBIG stock, representing a little-known biotech company, is taking off today. Here's what you need to know.

BBLG Stock Alert: What Is Going on With Bone Biologics Today?

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #BoneBiologics--Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that it closed a public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share of common stock and one warrant to

Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

JERSEY CITY, N.J., Oct. 15, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public offering of 1,510,455 units of Bone Biologics (NASDAQ: BBLG) at an offering price of $5.25 per unit for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering

JERSEY CITY, N.J., Oct. 13, 2021 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the pricing of an underwritten public offering of 1,510,455 units of Bone Biologics (NASDAQ: BBLG) at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market

BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #BoneBiologics--Bone Biologics Corp. (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its underwritten public offering of 1,510,455 units of securities at an offering price of $5.25 per unit, for total gross proceeds of $7.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share of common stock and

Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split

News for Bone Biologics Corp Stock (BBLG)